Article Figures & Data
Figures
- FIGURE 1.
Binding of 111In-DTPA-A20FMDV2 peptide in lungs of fibrotic mice was detected at low level in lungs of saline-treated mice (A) with no evidence of parenchymal damage on the corresponding CT scans (C). Level of 111In- DTPA-A20FMDV2 binding was greatly increased in bleomycin-treated animals (B), which showed clear evidence of parenchymal damage in axial CT scans (D).
- FIGURE 2.
Levels of binding in lungs, expressed as percentage of initial activity of 111In-labeled peptide, were compared in bleomycin- (n = 18) and saline- (n = 8) treated mice. Binding of 111In-DTPA-A20FMDVran peptide in lungs of saline- (n = 6) or bleomycin- (n = 8) treated mice was also assessed. Data are presented as mean ± SEM. ****P < 0.0001. **P < 0.01.
- FIGURE 3.
Axial SPECT/CT scans of thorax detected binding of 111In-DTPA-A20FMDV2 in lungs of bleomycin-treated animals receiving αvβ6-blocking antibody (A) or IgG2a isotype control (B) (2.5 mg/kg) 24 h before imaging. Effect of αvβ6-blocking (C) and IgG2a isotype control (D) antibodies on binding of 111In-DTPA-A20FMDV2 was also assessed in saline-treated mice.
- FIGURE 4.
Levels of binding in lungs, expressed as percentage of initial activity of 111In-labeled peptide were quantified in saline- (n = 6) or bleomycin- (n = 5) treated animals pretreated with αvβ6-blocking antibody or mice pretreated with IgG2a isotype control (n = 4/group). Data are presented as mean ± SEM. *P < 0.05. ****P < 0.0001.
- FIGURE 5.
Binding of 111In-DTPA-A20FMDV2 to αvβ6 integrins was assessed in lungs of bleomycin-instilled mice (n = 6/group) and saline-treated mice (n = 4/group), and levels of peptide binding were compared after repeated scans at 2 and 4 wk after administration.
- FIGURE 6.
Correlation of 111In-DTPA-A20FMDV2 binding within lungs at 28 d after saline (white circles; n = 3) or bleomycin (black circles; n = 3) with epithelial αvβ6 expression in lungs (A). Correlation of 111In-DTPA-A20FMDV2 binding at day 28 (B) and day 14 (C) after saline (n = 4) or bleomycin (n = 6) treatment with lung hydroxyproline levels on day 28.
Additional Files
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis
- Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies
- Visualisation of interstitial lung disease by molecular imaging of integrin {alpha}v{beta}3 and somatostatin receptor 2
- A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin {alpha}v{beta}6
- Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis
- Identification of a Novel ITG{alpha}v{beta}6-Binding Peptide Using Protein Separation and Phage Display
- Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models
- In Vivo PET Imaging of the Cancer Integrin {alpha}v{beta}6 Using 68Ga-Labeled Cyclic RGD Nonapeptides
- Matrix Metalloproteinase-Targeted Imaging of Lung Inflammation and Remodeling
- Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin {alpha}v{beta}6 Expression
- {alpha}v{beta}6 integrin may be a potential prognostic biomarker in interstitial lung disease
- Endotyping idiopathic pulmonary fibrosis should improve outcomes for all patients with progressive fibrotic lung disease
- Influenza Promotes Collagen Deposition via {alpha}v{beta}6 Integrin-mediated Transforming Growth Factor {beta} Activation
- Novel approaches to pulmonary fibrosis